Alexander R Lyon

List of Publications by Year
in descending order

144 papers	20,068 citations	20759 60 h-index	11899 134 g-index
145 all docs	145 docs citations	145 times ranked	19613 citing authors

#	Article	IF	Citations
1	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
2	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
3	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal, 2018, 39, 2032-2046.	1.0	972
4	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
5	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 8-27.	2.9	835
6	Stress (Takotsubo) cardiomyopathyâ€”a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 22-29.	3.3	694
7	High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a Î² ₂ -Adrenergic Receptor/G _i â€“Dependent Manner. Circulation, 2012, 126, 697-706.	1.6	625
8	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 2020, 31, 171-190.	0.6	582
9	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. European Heart Journal, 2018, 39, 2047-2062.	1.0	521
10	Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncology, The, 2018, 19, e447-e458.	5.1	376
11	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet, The, 2016, 387, 1178-1186.	6.3	373
12	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020,	2.9	364
13	Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6854-6859.	3.3	334
14	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	1.8	311
15	Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet, The, 2019, 394, 1041-1054.	6.3	294
16	Epidemiology and pathophysiology of Takotsubo syndrome. Nature Reviews Cardiology, 2015, 12, 387-397.	6.1	283
17	Myocarditis in the Setting of Cancer Therapeutics. Circulation, 2019, 140, 80-91.	1.6	278
18	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239

#	Article	IF	Citations
19	tools of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	2.9	234
20	Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 2018, 138, 678-691.	1.6	229
21	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
22	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	2.9	223
23	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
24	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	1.0	212
25	Cardio-Oncology Services: rationale, organization, and implementation. European Heart Journal, 2019, 40, 1756-1763.	1.0	195
26	Genetic Variants Associated With Cancer Therapyâ€"Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195
27	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195
28	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	2.9	184
29	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
30	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	1.2	179
31	A conducting polymer with enhanced electronic stability applied in cardiac models. Science Advances, 2016, 2, e1601007.	4.7	173
32	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€"European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
33	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European Heart Journal, 2020, 41, 1720-1729.	1.0	154
34	SERCA2a Gene Transfer Decreases Sarcoplasmic Reticulum Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 362-372.	2.1	147
35	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitorâ€"Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
36	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	2.9	138

#	Article	IF	Citations
37	Takotsubo syndrome: aetiology, presentation and treatment. Heart, 2017, 103, 1461-1469.	1.2	136
38	Pathophysiology of Takotsubo Syndrome. Journal of the American College of Cardiology, 2021, 77, 902-921.	1.2	125
39	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	1.0	123
40	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	2.9	115
41	Activity and outcomes of a cardioâ€oncology service in the United Kingdomâ€"a fiveâ€year experience. European Journal of Heart Failure, 2018, 20, 1721-1731.	2.9	105
42	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	2.9	105
43	Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling. Journal of Molecular and Cellular Cardiology, 2014, 67, 38-48.	0.9	103
44	Plasticity of Surface Structures and Î² ₂ -Adrenergic Receptor Localization in Failing Ventricular Cardiomyocytes During Recovery From Heart Failure. Circulation: Heart Failure, 2012, 5, 357-365.	1.6	102
45	Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. Cardiovascular Research, 2017, 113, 1743-1752.	1.8	102
46	Microdomain-Specific Modulation of L-Type Calcium Channels Leads to Triggered Ventricular Arrhythmia in Heart Failure. Circulation Research, 2016, 119, 944-955.	2.0	101
47	Sodiumâ€"glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
48	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in Î²-adrenergic signaling and enhances apoptosis. Cell Death and Disease, 2015, 6, e1754-e1754.	2.7	98
49	Standard and Advanced Echocardiography in Takotsubo (Stress) Cardiomyopathy: Clinical and Prognostic Implications. Journal of the American Society of Echocardiography, 2015, 28, 57-74.	1.2	97
50	Myocardial T1 and T2 Mapping by Magnetic Resonance in PatientsÂWithÂImmune Checkpoint Inhibitorâ€"Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	1.2	97
51	Gene therapy: targeting the myocardium. Heart, 2008, 94, 89-99.	1.2	94
52	The Role of Biomarkers in Cardio-Oncology. Journal of Cardiovascular Translational Research, 2020, 13, 431-450.	1.1	92
53	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
54	Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ: British Medical Journal, 2018, 363, k3845.	2.4	91

#	Article	IF	Citations
55	Gut microbial degradation of organophosphate insecticides-induces glucose intolerance via gluconeogenesis. Genome Biology, 2017, 18, 8.	3.8	88
56	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. JACC: CardioOncology, 2021, 3, 35-47.	1.7	80
57	Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 55.	0.4	69
58	Cardiac contractility modulation therapy in advanced systolic heart failure. Nature Reviews Cardiology, 2013, 10, 584-598.	6.1	67
59	Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Advances, 2018, 2, 1633-1644.	2.5	66
60	Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in BreastÂCancer. JACC: CardioOncology, 2019, 1, 68-79.	1.7	66
61	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
62	Renal denervation in heart failure with preserved ejection fraction (<scp>RDTâ€PEF</scp>): a randomized controlled trial. European Journal of Heart Failure, 2016, 18, 703-712.	2.9	62
63	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
64	Microtubule-Dependent Mitochondria Alignment Regulates Calcium Release in Response to Nanomechanical Stimulus in Heart Myocytes. Cell Reports, 2016, 14, 140-151.	2.9	55
65	T-tubule remodelling disturbs localized Î²2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure. Cardiovascular Research, 2017, 113, 770-782.	1.8	53
66	Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in Î²2AR-cAMP Responsiveness in Murine Hearts. Cell Reports, 2018, 23, 459-469.	2.9	51
67	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	1.8	51
68	Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials. Hypertension, 2015, 65, 401-406.	1.3	44
69	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.4	42
70	Diagnostic criteria for takotsubo syndrome: A call for consensus. International Journal of Cardiology, 2014, 176, 274-276.	0.8	41
71	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Failure Reviews, 2019, 24, 915-925.	1.7	39
72	Cardiovascular changes during peanut-induced allergic reactions in human subjects. Journal of Allergy and Clinical Immunology, 2021, 147, 633-642.	1.5	37

#	Article	IF	Citations
73	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	2.9	37
74	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncologyâ€"Part 1: acute coronary syndromes and acute pericardial diseases. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 947-959.	0.4	37
75	Pathophysiology of Takotsubo Syndrome. Circulation Journal, 2014, 78, 1550-1558.	0.7	36
76	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
77	Pathophysiology of <scp>T</scp>akotsubo syndromeÂâ€"Âa joint scientific statement from the Heart Failure Association <scp>T</scp>akotsubo Syndrome Study Group and Myocardial Function Working Group of the <scp>E</scp>uropean Society of CardiologyÂâ€"ÂPart 1: overview and the central role for catecholamines and sympathetic nervous system. European Journal of Heart Failure, 2022, 24, 257-273.	2.9	36
78	Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device â€" the SERCA-LVAD TRIAL. Gene Therapy, 2020, 27, 579-590.	2.3	35
79	Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Research and Treatment, 2021, 188, 149-163.	1.1	35
80	Recent advances in cardioâ€oncology: a report from the â€˜Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019â€™. ESC Heart Failure, 2019, 6, 1140-1148.	1.4	34
81	Pathophysiology of Takotsubo syndromeÂâ€" a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of CardiologyÂâ€"ÂPart 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Failure, 2022, 24, 274-286.	2.9	34
82	The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. Human Gene Therapy, 2015, 26, 293-304.	1.4	33
83	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	0.8	33
84	Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer, 2016, 16, 912.	1.1	30
85	Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. Cardiovascular Research, 2022, 118, 1758-1770.	1.8	30
86	Cardiac Atrophy and Heart Failure In Cancer. Cardiac Failure Review, 2017, 03, 62.	1.2	29
87	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	157.7	29
88	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	0.7	29
89	Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. International Journal of Cardiology, 2020, 317, 167-173.	0.8	25
90	Computational modeling of Takotsubo cardiomyopathy: effect of spatially varying Î²-adrenergic stimulation in the rat left ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1487-H1496.	1.5	24

#	Article	IF	Citations
91	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circulation: Heart Failure, 2021, 14, e008209.	1.6	24
92	Shortâ€•and Longâ€Term Clinical Outcomes for Patients With Takotsubo Syndrome and Patients With Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. Journal of the American Heart Association, 2021, 10, e017290.	1.6	24
93	Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts. Cardiovascular Research, 2015, 105, 31-43.	1.8	23
94	Heart failure with preserved ejection fraction. Clinical Medicine, 2018, 18, s24-s29.	0.8	23
95	Modernâ€day cardioâ€oncology: a report from the â€˜Heart Failure and World Congress on Acute Heart Failure 2018â€™. ESC Heart Failure, 2018, 5, 1083-1091.	1.4	23
96	Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart, 2021, 107, 1327-1335.	1.2	23
97	Does Cardiovascular Mortality OvertakeÂCancer Mortality During CancerÂSurvivorship?. JACC: CardioOncology, 2022, 4, 113-123.	1.7	23
98	Cardio-oncology: Concepts and practice. Indian Heart Journal, 2016, 68, S77-S85.	0.2	20
99	Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies. Current Oncology Reports, 2019, 21, 45.	1.8	20
100	Proteasome Inhibitors as a Potential Cause of Heart Failure. Heart Failure Clinics, 2017, 13, 289-295.	1.0	19
101	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800.	1.0	18
102	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 2017, 19, 718-727.	2.9	17
103	Heart failure resulting from cancer treatment: still serious but an opportunity for prevention. Heart, 2019, 105, 6-8.	1.2	16
104	The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998â€“2014. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 90-94.	1.4	15
105	Monitoring the heart during cancer therapy. European Heart Journal Supplements, 2019, 21, M44-M49.	0.0	14
106	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology, 2020, 156, 545-551.	0.6	14
107	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	1.0	14
108	Takotsubo syndrome in Heart Failure and World Congress on Acute Heart Failure 2019: highlights from the experts. ESC Heart Failure, 2020, 7, 400-406.	1.4	13

#	Article	IF	Citations
109	Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. Current Heart Failure Reports, 2020, 17, 397-408.	1.3	12
110	Stressing the Importance of Cardiac Assessment in Pheochromocytoma â^—. Journal of the American College of Cardiology, 2016, 67, 2375-2377.	1.2	11
111	Chronic intake of 4-Methylimidazole induces Hyperinsulinemia and HypoglycaemiaÂvia Pancreatic Beta Cell Hyperplasia and Glucose Dyshomeostasis. Scientific Reports, 2018, 8, 17037.	1.6	9
112	Cardiovascular disease following breast cancer treatment: can we predict who will be affected?. European Heart Journal, 2019, 40, 3921-3923.	1.0	9
113	Cardiovascular events in cancer survivors. Seminars in Oncology, 2019, 46, 426-432.	0.8	8
114	Gene Therapy for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2014, 129, 2633-2635.	1.6	7
115	A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H465-H475.	1.5	7
116	Effects of renal denervation on vascular remodelling in patients with heart failure and preserved ejection fraction: A randomised control trial. JRSM Cardiovascular Disease, 2017, 6, 204800401769098.	0.4	7
117	Is P2Y12 inhibitor therapy associated with an increased risk of cancer?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 100-104.	1.4	7
118	Cardiotoxicity Following Cancer Treatment. Ulster Medical Journal, 2017, 86, 3-9.	0.2	7
119	Authors' response to â€œStress (Takotsubo) cardiomyopathyâ€”a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunningâ€• Nature Clinical Practice Cardiovascular Medicine, 2008, 5, E2-E2.	3.3	6
120	Use of cardiac MRI to diagnose Takotsubo syndrome. Nature Reviews Cardiology, 2015, 12, 669-669.	6.1	6
121	Cardio-oncology: rationale, aims and future directions. Current Opinion in Supportive and Palliative Care, 2021, 15, 134-140.	0.5	6
122	Cardio-oncology for the general cardiologist. Heart, 2021, 107, 1254-1266.	1.2	6
123	Gene therapy for GM1 gangliosidosis: challenges of translational medicine. Annals of Translational Medicine, 2015, 3, S28.	0.7	6
124	The year in cardiovascular medicine 2021: cardio-oncology. European Heart Journal, 2022, , .	1.0	6
125	The effect of headâ€up tilt upon markers of heart rate variability in patients with atrial fibrillation. Annals of Noninvasive Electrocardiology, 2018, 23, e12511.	0.5	5
126	What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. Clinical Oncology, 2021, 33, 483-493.	0.6	5

#	Article	IF	Citations
127	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	2.2	5
128	A cross-sectional imaging study to identify organs at risk of thermal injury during renal artery sympathetic denervation. International Journal of Cardiology, 2015, 197, 235-240.	0.8	4
129	Challenges of Chronic Cardiac Problems in Survivors of Takotsubo Syndrome. Heart Failure Clinics, 2016, 12, 551-557.	1.0	4
130	Device closure for patent foramen ovale in patients with cryptogenic stroke: which patients should get it?. European Heart Journal Supplements, 2020, 22, M43-M50.	0.0	3
131	Takotsubo cardiomyopathy. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 96-103.	0.2	2
132	Break a sweat to reduce cardiotoxicity â€“ the benefits of exercise training during anthracycline chemotherapy. European Journal of Preventive Cardiology, 2019, 26, 301-304.	0.8	2
133	CMR unveiling the cause of post CoVid-19 infection chest pain. International Journal of Cardiovascular Imaging, 2021, 37, 2025-2026.	0.7	2
134	Cardiac Stem Cell Therapy and Arrhythmogenicity: Prometheus and the arrows of Apollo and Artemis. Journal of Cardiovascular Translational Research, 2008, 1, 207-216.	1.1	1
135	Microcirculatory dysfunction and autonomic disturbance in Takotsubo syndrome. Nature Reviews Cardiology, 2015, 12, 497-497.	6.1	1
136	Bubbles in Ballooning: Safety and Utility. Journal of the American Society of Echocardiography, 2015, 28, 845.	1.2	1
137	Irreversible apical ballooning may also occur. British Journal of Hospital Medicine (London, England:) Tj ETQq1 1 0.784314 rgBT /Overl	0.2	0
138	2â€...Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous takotsubo syndrome â€“ insights from exercise echocardiography. , 2019, , .		0
139	P1497Reversible exercise-induced left ventricular dysfunction in symptomatic patients with previous Takotsubo syndrome - Insights from exercise echocardiography. European Heart Journal, 2019, 40, .	1.0	0
140	Cancer and cardiovascular disease â€“ Authors' reply. Lancet, The, 2020, 395, 1904-1905.	6.3	0
141	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma.. Journal of Clinical Oncology, 2015, 33, e21516-e21516.	0.8	0
142	Risk of hypertension (HTN) and malignant hypertension (mHTN) in patients treated for multiple myeloma (MM).. Journal of Clinical Oncology, 2016, 34, 8049-8049.	0.8	0
143	The year in cardiology 2019: heart failure. Revista Romana De Cardiologie, 2020, 30, 185-204.	0.0	0
144	Ventricular arrhythmias in patients with immune checkpoint inhibitor myocarditis. European Heart Journal, 2021, 42, .	1.0	0